Technology area: Chemistry & Materials
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
BEIJING CELL-FUSION BIOTECHNOLOGY CO., LTD. is active in the Chemistry & Materials technology area. The portfolio currently includes 1 pending office action, indicating a focused approach to its current intellectual property filings. This activity is confined to 1 distinct examiner and 1 distinct art unit, which suggests that the company is prioritizing a specific chemical technology.
The busiest examiner, HUANG, MICKEY NMN, is managing 1 pending office action. As the portfolio only features 1 distinct examiner for its pending work, the prosecution process is centralized, making the examiner's specific feedback the primary factor in the portfolio's advancement. Practitioners should analyze the historical data for HUANG, MICKEY NMN to anticipate potential challenges.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUANG, MICKEY NMN | 1 | 60.0% | +48.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17755664 | DEVICE FOR EVALUATING NEUROVIRULENCE OF MUMPS VIRUS | HUANG, MICKEY NMN | — |
| Art Unit | Apps |
|---|---|
| 1758 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17755664 | DEVICE FOR EVALUATING NEUROVIRULENCE OF MUMPS VIRUS | HUANG, MICKEY NMN | 1758 | §103 | Final Rejection | — | Pending | May 04, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBEIJING CELL-FUSION BIOTECHNOLOGY CO., LTD. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Mickey Nmn Huang has the most, with 1 of BEIJING CELL-FUSION BIOTECHNOLOGY CO., LTD.'s pending office actions.
Mostly Chemistry & Materials (USPTO Tech Center 1700), based on where its pending office actions are examined.
